Centene (CNC)
NYSE: CNC · Healthcare Plans · St Louis, MO
Our rating: Positive
Call changed from Cautious to Positive at $67.05, moderate conviction, October 28, 2026.
Breaks if: The Positive call is wrong if free cash flow for any two consecutive reported quarters implies an annualized run rate below $2.0 billion — that would mean the gap between cash and reported earnings reflects genuine deterioration in cash generation, not accounting noise. On price, a sustained close below $47 over any 20-trading-day window would suggest the market has identified a structural impairment the current thesis does not account for.
Key figures
| Market value | $31.6B |
|---|---|
| Revenue, last 12 months | $178.9B |
| Net income, last 12 months | $1.5B |
| Free cash flow, last 12 months | $3.9B |
| Price to earnings | 21.6× |
| Free cash flow yield | 12.5% |
| Dividend yield | 0.0% |
| Operating margin | 0.6% |
| Return on equity | 6.8% |
| Beta to the S&P 500 | 0.23 |
| Volatility, annualized | 49.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $45.1B | 0.5% | $-0.14 | −$3.9B |
| June 30, 2026 | $44.4B | 4.5% | $2.19 | $3.4B |
| March 31, 2026 | $44.7B | 5.1% | $3.11 | $4.2B |
| December 31, 2025 | $44.7B | 23.2% | $-2.24 | $224M |
| September 30, 2025 | $44.9B | 21.7% | $-13.50 | $1.1B |
| June 30, 2025 | $42.5B | 18.1% | $-0.51 | $1.6B |
| March 31, 2025 | $42.5B | 16.9% | $2.63 | $1.4B |
| December 31, 2024 | $36.3B | 2.7% | $0.62 | −$741M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $48.4B: Claude 8%, Gemini 35%, Mistral 30%
- Diluted earnings per share are above zero: Claude 42%, Gemini 75%, Mistral 70%
- Free cash flow for the quarter is at least $0.22B: Claude 28%, Gemini 40%, Mistral 60%
13 ledger entries and 54 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.